COMMUNIQUÉS West-GlobeNewswire

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
28/09/2026
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with [...]
Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors
28/09/2026
London, September 28, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Eva Ehrnrooth, MD, PhD, as Executive Head of Clinical Development and Chau Khuong to its Board of Directors. Dr [...]
A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China
28/09/2026
SHENZHEN, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Recently in Shenzhen, China, the Center for Integrative Medicine for Chronic Diseases and the Center for Natural Diabetes Therapy at Shenzhen Hengsheng Hospital—a [...]
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
28/09/2026
Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
28/09/2026
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑ [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
28/09/2026
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7
28/09/2026
September 28, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
28/09/2026
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 Cash runway guidance remains unchanged from July 30, 2026 2 Topline results of the Phase 3 NATiV3 clinical trial [...]
Inventiva publie ses résultats financiers non audités du premier semestre 2026 et fait le point sur ses activités
28/09/2026
Trésorerie et équivalents de trésorerie à 166,1 millions d’euros et dépôts à court terme 1 à 67,8 millions d’euros au 30 juin 2026 Horizon de trésorerie inchangé par rapport au 30 juillet 2026 2 Résultats principaux de [...]
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
28/09/2026
€11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026 The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash [...]
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2026 et fait un point sur ses activités
28/09/2026
11,1 millions d’euros de trésorerie au 30 juin 2026 ; horizon de financement confirmé jusqu’à fin décembre 2026 La Société poursuit activement ses interactions avec les investisseurs institutionnels aux États-Unis et en [...]
JJP Biologics to Present Data Showing the Potential of Nebaprubart for Linear IgA Dermatosis (LAD) at Two Key Upcoming Scientific Conferences
28/09/2026
Positive interim data from Phase Ib proof-of-concept trial will be presented at the IPPF Scientific Symposium on Pemphigus and Pemphigoid and at EADV Congress 2026 Data positions nebaprubart as a potential therapy [...]
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
28/09/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Penn Medicine and IBA Launch Joint Venture to Advance Proton Therapy and Radiation Oncology Program Development Worldwide
28/09/2026
New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle PHILADELPHIA, Pa., and [...]
Penn Medicine et IBA lancent une joint-venture pour accompagner le développement de la protonthérapie et des programmes de radio-oncologie dans le monde
28/09/2026
Une nouvelle offre de services d’experts afin d’aider les établissements de santé à développer, déployer et optimiser leurs programmes de protonthérapie et de radio-oncologie sur l’ensemble des soins PHILADELPHIE, [...]
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
28/09/2026
First-in-class KRAS-payload leveraging synchronized EGFR inhibition HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: [...]
ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026
27/09/2026
Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177 Lu-edotreotide compared to those receiving non-radiopharmaceutical systemic [...]
The Future of Radiotherapy is Here: Siemens Healthineers Launches Accela
27/09/2026
The Accela radiotherapy solution is engineered around NeoArc dynamic modulated arc therapy (DMAT), a breakthrough technique combining speed and precision Boston, Sept. 27, 2026 (GLOBE NEWSWIRE) -- Siemens Healthineers [...]
TamaBio to Showcase Synthetic Biomembrane Technology at ACS Clinical Congress 2026 in Washington, D.C.
27/09/2026
Japanese medical technology company will introduce U.S. surgeons and industry partners to its DuraBeam® and PeriBeam® devices WASHINGTON, Sept. 27, 2026 (GLOBE NEWSWIRE) -- TamaBio Company Limited , a Japanese medical [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

Contenu:

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

Contenu:

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

Contenu:

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Contenu:

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Contenu:

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Contenu:

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Contenu:

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.